FDA-ready doesn’t always mean Europe-ready, and for many viral vector programmes, that realisation comes too late
Across the industry, viral vector analytical strategies are still overwhelmingly built around FDA expectations. That is not only logical, but often necessary; however, it can introduce risk. When programmes turn towards Europe, teams may find that an FDA-aligned package is not automatically fit for EU release.
The differences are not always dramatic, but they can be decisive. EU expectations often need to be built into development earlier than teams anticipate, with particular emphasis on method suitability, potency strategy, biological relevance, and orthogonal evidence to support critical quality attributes. For example, potency assays that are acceptable as surrogate or early-stage tools in the US may require greater biological relevance or additional supporting data to be suitable for EU release or later-stage regulatory expectations. These considerations should shape assay design from the outset, yet they are often underestimated during early and mid-stage development.
This is where regulatory expectations become operational reality. Viral vector-based ATMPs typically require EU-based testing, mandatory Qualified Person (QP) release, and in-country oversight. Mutual recognition does not apply. As programmes advance, an analytical strategy that works well in the US can quickly become misaligned with current European release requirements.
Eurofins BioPharma Product Testing sees this challenge repeatedly. Programmes reach later stages needing method redevelopment, duplicate testing to satisfy EU expectations, or urgent bridging work to enable QP release. The result is rarely scientific failure, but avoidable delay at the point where flexibility is lowest and timelines matter most.
The solution is not reactive adjustment, but early global alignment. Viral vector programmes progress more efficiently when analytical strategies are designed to meet both FDA and EMA expectations from the beginning.
Eurofins BioPharma Product Testing Ireland enables exactly that, combining EU-based GMP testing, regulatory insight, and global network strength to deliver a single, aligned analytical strategy that reduces duplication, supports QP release, and keeps viral vector programmes moving confidently from development through to commercial release. For more information, visit: Gene Therapies | Eurofins